vimarsana.com
Home
Live Updates
Horizon Therapeutics plc Reports First-Quarter 2023 Financia
Horizon Therapeutics plc Reports First-Quarter 2023 Financia
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
First-Quarter 2023 Results:
-- Net Sales of $832.1 Million --
-- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million --
-- TEPEZZA® Net Sales of $405.3 Million --
--... | May 3, 2023
Related Keywords
Ireland ,
Japan ,
Ukraine ,
United States ,
Russia ,
Tim Walbert ,
Viela Bio Inc ,
Companies To Work ,
Nasdaq ,
Top Biotechnology Pharmaceutical Company ,
Facebook ,
Clinical Program Expected To ,
Instagram ,
Amgen Inc ,
Linkedin ,
Apotex Inc ,
Amgen ,
United States Federal Trade Commission ,
Twitter ,
Net Sales ,
Recent Company Highlights ,
Positive Topline Data ,
Low Clinical Activity Score ,
Thyroid Eye Disease ,
Specify Treatment ,
Disease Activity ,
Second Population ,
Syndrome Phase ,
Only Phase ,
Syndrome Trial ,
Primary Endpoint ,
Both Patient Populations ,
Program Expected ,
Two Daxdilimab Phase ,
Discoid Lupus Erythematosus ,
Expect Amgen Transaction ,
Work For ,
Pharmaceutical Company ,
Third Consecutive ,
Quarterly Report ,
Investor Relations ,
Regarding Use ,
Consolidated Statements ,
Months Ended March ,
Consolidated Balance Sheets ,
Cash Flows ,
Earnings Per Share ,
Per Share ,
Operating Cash Flow ,
Rate Reconciliation ,
Income Statement Line Items ,
Three Months Ended March ,
Lake Forest ,
Viela Bio ,
Horizon Therapeutics Public Limited Company Stock Exchange ,
News ,
Information ,
Press Release ,
023 ,
Pet ,
Sales ,
F ,
Billion ,
Aap ,
Income ,
Djusted ,
Bitda ,
Illion Hznp Ie00bqpvqz61 ,